Notícias

Moderna (MRNA), TG Therapeutics (TGTX), and Agios Pharmaceuticals (AGIO) will see increased scrutiny

Moderna's growth story is just beginning.

Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.

The Morning Bull - US Market Morning Update Monday, Jul, 6 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 futures up about 0.4% and E-mini Nasdaq-100 futures up around 1.2%, as investors weigh cooling market anxiety against a packed data week. Volatility gauges like VIX futures are down roughly 2%, which means investors are currently pricing in a calmer trading day. At the same time, the ISM Services PMI, existing home sales, and the Federal Reserve meeting...

Moderna, Inc. (NASDAQ:MRNA) was among the stocks Jim Cramer commented on as he advised investors on how to take advantage of Wednesday’s market rotation. Cramer highlighted the stock’s significant gains during the year, as he said: If you look at the market’s best performers year to date, nearly all of them are either companies that […]

The stock market trades largely sideways and oil dips to pre-Iran war prices heading into the final week before Q2 earnings. Here's what to watch.

MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season.

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism bordering on avoidance. The Cambridge, Massachusetts, company had become synonymous with the pandemic trade, and Cramer’s enthusiasm faded as demand for Covid-era vaccines dried ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

The Morning Bull - US Market Morning Update Friday, Jul, 3 2026 US stock futures are slightly weaker this morning, with S&P 500 contracts edging down around 0.01%, as investors weigh softer US data against rising borrowing costs. The US private sector added 98,000 jobs in June, fewer than in May and below forecasts, which hints that hiring is cooling but unemployment near 4.3% still points to plenty of people in work. At the same time, the ISM Manufacturing PMI sits at 53.3, so factories are...

Many of this year’s hottest stocks are the biggest decliners in premarket trading Thursday after sharp drops in the previous session.

Shares of Palo Alto Networks, American Airlines Group, and Moderna climbed amid a series of positive catalysts for the companies.

Seven S&P 500 stocks have already tripled in 2026, with memory giant Sandisk far in front All are AI stocks.

Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.

The list is dominated by semiconductor and computer-hardware manufacturers.

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Comcast created a stir among communication services stocks with a plan to spin off its media and entertainment assets into a new publicly traded company.

Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.

Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in MRNA shares.

The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...

Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline.

Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.

Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.

<body><p>STORY: U.S. stocks ended marginally lower on Friday, with the Dow and S&P 500 each shedding less than a tenth of a percent, and the Nasdaq losing about a quarter of a percent.</p><p>AI-related chip stocks suffered steep declines as some investors worry that the massive spending to build AI data centers may take too long to pay off.</p><p>Robert Conzo is CEO and managing director of The Wealth Alliance.</p><p>"The AI ship, although we love the technology, everyone loves the idea, it's like a cruise ship where the captain knows where they're going, the passengers don't know where this is going, passengers get nervous. The captain is the CEOs of these companies, putting billions and billions and billions of dollars of infrastructure into the AI. The market is the passengers saying, 'When are we going to be profitable here? At what point does profitability come to play?' Analysts are saying 2030, could be longer. And when prices go up, up, up, up higher, suddenly you start to question that value."</p><p>A report that OpenAI was considering delaying its public debut until next year also weighed on risk sentiment related to AI stocks.</p><p>:: Apple</p><p>Elsewhere in the market, shares of Apple rallied more than 3% and partly rebounded from a selloff a day earlier. The tech giant on Thursday raised iPad and MacBook prices, blaming soaring memory and storage chip costs.</p><p>:: Archive</p><p>Shares of ON Semiconductor tumbled almost 24% after the company agreed to acquire chip maker Synaptics in an all-stock deal valued at about $7 billion. Shares of Synaptics dipped more than 3.5%.</p><p>:: Moderna</p><p>On the flipside, shares of Moderna surged almost 13% to their highest level since 2024 after the drug developer hosted an investor event and showcased its pipeline.</p></body>

US equity indexes were lower on Friday amid a sell-off in technology stocks and despite a decline in

Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.

Yahoo Finance's Jared Blikre takes a closer look at some of Friday's trending tickers and stories, including Moderna (MRNA), Netflix (NFLX), and ON Semiconductor (ON).